Serial measurement of hepatic lipids during chemotherapy in patients with colorectal cancer: A 1H MRS study

NMR in Biomedicine

Volumn 26, Issue 2, 2013, Pages 204-212

  Qi, Jing ^a   Fong, Yuman ^a   Saltz, Leonard ^a   D'Angelica, Michael I ^a   Kemeny, Nancy E ^a   Gonen, Mithat ^a   Shia, Jinru ^a   Shukla Dave, Amita ^a   Jarnagin, William M ^a   Do, Richard K G ^a   Schwartz, Lawrence H ^b   Koutcher, Jason A ^a   Zakian, Kristen L ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b College of Physicians and Surgeons ^*  (United States)

Author keywords

Fat; FOLFOX; Imaging; Liver; Steatosis

Indexed keywords

5-FLUOROURACIL; ARTERIAL INFUSION; BREATH HOLDS; COLORECTAL CANCER; FAT; FOLFOX; FOLINIC ACID; HEPATIC STEATOSIS; HIGH PROBABILITY; IRINOTECAN; LIPID LEVELS; LIVER INJURIES; OXALIPLATIN; REPRODUCIBILITIES; STEATOSIS; TIME COURSE;

CHEMOTHERAPY; DISEASES; DRUG PRODUCTS; IMAGING TECHNIQUES; LIPIDS; LIVER;

PATIENT TREATMENT;

FLOXURIDINE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; LIPID; OXALIPLATIN; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; BREATH HOLDING; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; COLORECTAL CANCER; CONTROLLED STUDY; DISEASE SEVERITY; FATTY LIVER; FEMALE; HISTOLOGY; HUMAN; LIPID LIVER LEVEL; MALE; OUTCOME ASSESSMENT; PATIENT MONITORING; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTON NUCLEAR MAGNETIC RESONANCE; QUANTITATIVE ANALYSIS; TREATMENT DURATION;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; FATTY LIVER; FEMALE; HUMANS; LIPID METABOLISM; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MIDDLE AGED; PROTONS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

EID: 84872606001     PISSN: 09523480     EISSN: 10991492     Source Type: Journal    
DOI: 10.1002/nbm.2837     Document Type: Article

References (63)

1. Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, Maroun JA, Ackland SP, Locker PK, Pirotta N, Elfring GL, Miller LL. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N. Engl. J. Med. 2000; 343: 905-914.
2. Goldberg RM, Sargent DJ, Morton RF, Fuchs CS, Ramanathan RK, Williamson SK, Findlay BP, Pitot HC, Alberts SR. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J. Clin. Oncol. 2004; 22: 23-30.
3. Adam R, Delvart V, Pascal G, Valeanu A, Castaing D, Azoulay D, Giacchetti S, Paule B, Kunstlinger F, Ghemard O, Levi F, Bismuth H. Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival. Ann. Surg. 2004; 240: 644-657; discussion 657-658.
4. Fernandez FG, Ritter J, Goodwin JW, Linehan DC, Hawkins WG, Strasberg SM. Effect of steatohepatitis associated with irinotecan or oxaliplatin pretreatment on resectability of hepatic colorectal metastases. J. Am. Coll. Surg. 2005; 200: 845-853.
5. Cleary JM, Tanabe KT, Lauwers GY, Zhu AX. Hepatic toxicities associated with the use of preoperative systemic therapy in patients with metastatic colorectal adenocarcinoma to the liver. Oncologist 2009; 14: 1095-1105.
6. Vauthey JN, Pawlik TM, Ribero D, Wu TT, Zorzi D, Hoff PM, Xiong HQ, Eng C, Lauwers GY, Mino-Kenudson M, Risio M, Muratore A, Capussotti L, Curley SA, Abdalla EK. Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J. Clin. Oncol. 2006; 24: 2065-2072.
7. Pawlik TM, Olino K, Gleisner AL, Torbenson M, Schulick R, Choti MA. Preoperative chemotherapy for colorectal liver metastases: impact on hepatic histology and postoperative outcome. J. Gastrointest. Surg. 2007; 11: 860-868.
8. Chun YS, Laurent A, Maru D, Vauthey JN. Management of chemotherapy-associated hepatotoxicity in colorectal liver metastases. Lancet Oncol. 2009; 10: 278-286.
9. Rubbia-Brandt L, Audard V, Sartoretti P, Roth AD, Brezault C, Le Charpentier M, Dousset B, Morel P, Soubrane O, Chaussade S, Mentha G, Terris B. Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Ann. Oncol. 2004; 15: 460-466.
10. Bilchik AJ, Poston G, Curley SA, Strasberg S, Saltz L, Adam R, Nordlinger B, Rougier P, Rosen LS. Neoadjuvant chemotherapy for metastatic colon cancer: a cautionary note. J. Clin. Oncol. 2005; 23: 9073-9078.
11. Kooby DA, Fong Y, Suriawinata A, Gonen M, Allen PJ, Klimstra DS, DeMatteo RP, D'Angelica M, Blumgart LH, Jarnagin WR. Impact of steatosis on perioperative outcome following hepatic resection. J. Gastrointest. Surg. 2003; 7: 1034-1044.
12. McCormack L, Petrowsky H, Jochum W, Furrer K, Clavien PA. Hepatic steatosis is a risk factor for postoperative complications after major hepatectomy: a matched case-control study. Ann. Surg. 2007; 245: 923-930.
13. Vetelainen R, van Vliet A, Gouma DJ, van Gulik TM. Steatosis as a risk factor in liver surgery. Ann. Surg. 2007; 245: 20-30.
14. Longo R, Pollesello P, Ricci C, Masutti F, Kvam BJ, Bercich L, Croce LS, Grigolato P, Paoletti S, de Bernard B, Titibelli MD, Dalla Palma L. Proton MR spectroscopy in quantitative in vivo determination of fat content in human liver steatosis. J. Magn. Reson. Imaging 1995; 5: 281-285.
15. Szczepaniak LS, Nurenberg P, Leonard D, Browning JD, Reingold JS, Grundy S, Hobbs HH, Dobbins RL. Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population. Am. J. Physiol. Endocrinol. Metab. 2005; 288: E462-E468.
16. Urdzik J, Bjerner T, Wanders A, Weis J, Duraj F, Haglund U, Noren A. The value of pre-operative magnetic resonance spectroscopy in the assessment of steatohepatitis in patients with colorectal liver metastasis. J. Hepatol. 2011; 56: 640-646.
17. Hajek M, Dezortova M, Wagnerova D, Skoch A, Voska L, Hejlova I, Trunecka P. MR spectroscopy as a tool for in vivo determination of steatosis in liver transplant recipients. MAGMA 2011; 24: 297-304.
18. Roldan-Valadez E, Favila R, Martinez-Lopez M, Uribe M, Rios C, Mendez-Sanchez N. In vivo 3T spectroscopic quantification of liver fat content in nonalcoholic fatty liver disease: correlation with biochemical method and morphometry. J. Hepatol. 2010; 53: 732-737.
19. Hines CDG, Frydrychowicz A, Hamilton G, Tudorascu D, Vigen K, Yu H, McKenzie C, Sirlin C, Brittain J, Reeder S. T(1) independent, T(2) (*) corrected chemical shift based fat-water separation with multi-peak fat spectral modeling is an accurate and precise measure of hepatic steatosis. J. Magn. Reson. Imaging 2011; 33: 873-881.
20. Meisamy S, Hines CD, Hamilton G, Sirlin CB, McKenzie CA, Yu H, Brittain JH, Reeder SB. Quantification of hepatic steatosis with T1-independent, T2-corrected MR imaging with spectral modeling of fat: blinded comparison with MR spectroscopy. Radiology 2011; 258: 767-775.
21. Yokoo T, Bydder M, Hamilton G, Middleton MS, Gamst AC, Wolfson T, Hassanein T, Patton HM, Lavine JE, Schwimmer JB, Sirlin CB. Nonalcoholic fatty liver disease: diagnostic and fat-grading accuracy of low-flip-angle multiecho gradient-recalled-echo MR imaging at 1.5 T. Radiology 2009; 251: 67-76.
22. Yu H, Shimakawa A, Hines CD, McKenzie CA, Hamilton G, Sirlin CB, Brittain JH, Reeder SB. Combination of complex-based and magnitude-based multiecho water-fat separation for accurate quantification of fat-fraction. Magn. Reson. Med. 2011; 66: 199-206.
23. Springer F, Ehehalt S, Sommer J, Ballweg V, Machann J, Binder G, Claussen CD, Schick F. Assessment of relevant hepatic steatosis in obese adolescents by rapid fat-selective GRE imaging with spatial-spectral excitation: a quantitative comparison with spectroscopic findings. Eur. Radiol. 2011; 21: 816-822.
24. Bottomley P. Selective volume method for performing localized NMR spectroscopy. USA Patent 4, 480, 228. 1984.
25. 1H MR spectrum. NMR Biomed. 2011; 24: 784-790.
26. Gönen M (ed.). Analyzing Receiver Operating Characteristic Curves Using SAS. SAS Press: Cary, NC; 2007.
27. Obuchowski NA. Nonparametric analysis of clustered ROC curve data. Biometrics 1997; 53: 567-578.
28. Sorensen P, Edal AL, Madsen EL, Fenger C, Poulsen MR, Petersen OF. Reversible hepatic steatosis in patients treated with interferon alfa-2a and 5-fluorouracil. Cancer 1995; 75: 2592-2596.
29. Zeiss J, Merrick HW, Savolaine ER, Woldenberg LS, Kim K, Schlembach PJ. Fatty liver change as a result of hepatic artery infusion chemotherapy. Am. J. Clin. Oncol. 1990; 13: 156-160.
30. Peppercorn PD, Reznek RH, Wilson P, Slevin ML, Gupta RK. Demonstration of hepatic steatosis by computerized tomography in patients receiving 5-fluorouracil-based therapy for advanced colorectal cancer. B. J. Cancer 1998; 77: 2008-2011.
31. Moertel CG, Fleming TR, Macdonald JS, Haller DG, Laurie JA. Hepatic toxicity associated with fluorouracil plus levamisole adjuvant therapy. J. Clin. Oncol. 1993; 11: 2386-2390.
32. Ryan P, Nanji S, Pollett A, Moore M, Moulton CA, Gallinger S, Guindi M. Chemotherapy-induced liver injury in metastatic colorectal cancer: semiquantitative histologic analysis of 334 resected liver specimens shows that vascular injury but not steatohepatitis is associated with preoperative chemotherapy. Am. J. Surg. Pathol. 2010; 34: 784-791.
33. Aloia T, Sebagh M, Plasse M, Karam V, Levi F, Giacchetti S, Azoulay D, Bismuth H, Castaing D, Adam R. Liver histology and surgical outcomes after preoperative chemotherapy with fluorouracil plus oxaliplatin in colorectal cancer liver metastases. J. Clin. Oncol. 2006; 24: 4983-4990.
34. Makowiec F, Mohrle S, Neeff H, Drognitz O, Illerhaus G, Opitz OG, Hopt UT, zur Hausen A. Chemotherapy, liver injury, and postoperative complications in colorectal liver metastases. J. Gastrointest. Surg. 2011; 15: 153-164.
35. Browning JD, Szczepaniak LS, Dobbins R, Nuremberg P, Horton JD, Cohen JC, Grundy SM, Hobbs HH. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004; 40: 1387-1395.
36. Thomas EL, Hamilton G, Patel N, O'Dwyer R, Dore CJ, Goldin RD, Bell JD, Taylor-Robinson SD. Hepatic triglyceride content and its relation to body adiposity: a magnetic resonance imaging and proton magnetic resonance spectroscopy study. Gut 2005; 54: 122-127.
37. Kotronen A, Westerbacka J, Bergholm R, Pietilainen KH, Yki-Jarvinen H. Liver fat in the metabolic syndrome. J. Clin. Endocrinol. Metab. 2007; 92: 3490-3497.
38. Rijzewijk L, van der Meer R, Lubberink M, Lamb H, Romijn J, de Roos A, Twisk J, Heine R, Lammertsma A, Smit JWA, Diamant M. Liver fat content in type 2 diabetes: relationship with hepatic perfusion and substrate metabolism. Diabetes 2010; 59: 2747-2754.
39. 1H MR spectroscopy. Radiology 2010; 256: 159-168.
40. Petersen KF, Dufour S, Befroy D, Lehrke M, Hendler RE, Shulman GI. Reversal of nonalcoholic hepatic steatosis, hepatic insulin resistance, and hyperglycemia by moderate weight reduction in patients with type 2 diabetes. Diabetes 2005; 54: 603-608.
41. Cowin GJ, Jonsson JR, Bauer JD, Ash S, Ali A, Osland EJ, Purdie DM, Clouston AD, Powell EE, Galloway GJ. Magnetic resonance imaging and spectroscopy for monitoring liver steatosis. J. Magn. Reson. Imaging 2008; 28: 937-945.
42. Heath M, Kow L, Slavotinek J, Valentine R, Toouli J, Thompson C. Abdominal adiposity and liver fat content 3 and 12months after gastric banding surgery. Metab. Clin. Exp. 2009; 58: 753-758.
43. Thomas EL, Brynes A, Hamilton G, Patel N, Spong A, Goldin R, Frost G, Bell J, Taylor-Robinson S. Effect of nutritional counselling on hepatic, muscle and adipose tissue fat content and distribution in non-alcoholic fatty liver disease. World J. Gastroenterol. 2006; 12: 5813-5819.
44. Belfort R, Harrison S, Brown K, Darland C, Finch J, Hardies J, Balas B, Gastaldelli A, Tio F, Pulcini J, Berria R, Ma J, Dwivedi S, Havranek R, Fincke C, DeFronzo R, Bannayan G, Schenker S, Cusi K. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N. Engl. J. Med. 2006; 355: 2297-2307.
45. Allen-Mersh TG, Earlam S, Fordy C, Abrams K, Houghton J. Quality of life and survival with continuous hepatic-artery floxuridine infusion for colorectal liver metastases. Lancet 1994; 344: 1255-1260.
46. Kemeny N, Huang Y, Cohen AM, Shi W, Conti JA, Brennan MF, Bertino JR, Turnbull AD, Sullivan D, Stockman J, Blumgart LH, Fong Y. Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer. N. Engl. J. Med. 1999; 341: 2039-2048.
47. Power DG, Kemeny NE. Role of adjuvant therapy after resection of colorectal cancer liver metastases. J. Clin. Oncol. 2010; 28: 2300-2309.
48. House MG, Kemeny NE, Gonen M, Fong Y, Allen PJ, Paty PB, Dematteo RP, Blumgart LH, Jarnagin WR, D'Angelica MI. Comparison of adjuvant systemic chemotherapy with or without hepatic arterial infusional chemotherapy after hepatic resection for metastatic colorectal cancer. Ann. Surg. 2011; 254: 851-856.
49. Kingham TP, D'Angelica M, Kemeny N. Role of intra-arterial hepatic chemotherapy in the treatment of colorectal cancer metastases. J. Surg. Oncol. 2010; 102: 988-995.
50. Mikalauskas S, Mikalauskiene L, Bruns H, Nickkholgh A, Hoffmann K, Longerich T, Strupas K, Bchler M, Schemmer P. Dietary glycine protects from chemotherapy-induced hepatotoxicity. Amino Acids 2011; 40: 1139-1150.
51. Angulo P. Nonalcoholic fatty liver disease. N. Engl. J. Med. 2002; 346: 1221-1231.
52. Joshi D, O'Grady J, Dieterich D, Gazzard B, Agarwal K. Increasing burden of liver disease in patients with HIV infection. Lancet 2011; 377: 1198-1209.
53. Sulkowski MS, Mehta SH, Torbenson M, Afdhal NH, Mirel L, Moore RD, Thomas DL. Hepatic steatosis and antiretroviral drug use among adults coinfected with HIV and hepatitis C virus. AIDS 2005; 19: 585-592.
54. Berretta M, Lleshi A, Cappellani A, Bearz A, Spina M, Talamini R, Cacopardo B, Nunnari G, Montesarchio V, Izzi I, Lanzafame M, Nasti G, Basile F, Berretta S, Fisichella R, Schiantarelli CC, Garlassi E, Ridolfo A, Guella L, Tirelli U. Oxaliplatin based chemotherapy and concomitant highly active antiretroviral therapy in the treatment of 24 patients with colorectal cancer and HIV infection. Curr. HIV Res. 2010; 8: 218-222.
55. 1H-MR spectroscopy. Magn. Reson. Med. 2006; 55: 913-917.
56. Qayyum A, Nystrom M, Noworolski SM, Chu P, Mohanty A, Merriman R. MRI steatosis grading: development and initial validation of a color mapping system. Am. J. Roentgenol. 2012; 198: 582-588.
57. Reeder SB, Cruite I, Hamilton G, Sirlin CB. Quantitative assessment of liver fat with magnetic resonance imaging and spectroscopy. J. Magn. Reson. Imaging 2011; 34: 729-749.
58. Springer F, Machann J, Schwenzer NF, Ballweg V, Wurslin C, Schneider JH, Fritsche A, Claussen CD, Schick F. Quantitative assessment of intrahepatic lipids using fat-selective imaging with spectral-spatial excitation and in-/opposed-phase gradient echo imaging techniques within a study population of extremely obese patients: feasibility on a short, wide-bore MR scanner. Invest. Radiol. 2010; 45: 484-490.
59. 1H MR spectroscopy - a rapid and accurate technique. Radiology 2009; 252: 568-576.
60. Hamilton G, Middleton MS, Bydder M, Yokoo T, Schwimmer JB, Kono Y, Patton HM, Lavine JE, Sirlin CB. Effect of PRESS and STEAM sequences on magnetic resonance spectroscopic liver fat quantification. J. Magn. Reson. Imaging 2009; 30: 145-152.
61. McPherson S, Jonsson JR, Cowin GJ, O'Rourke P, Clouston AD, Volp A, Horsfall L, Jothimani D, Fawcett J, Galloway GJ, Benson M, Powell EE. Magnetic resonance imaging and spectroscopy accurately estimate the severity of steatosis provided the stage of fibrosis is considered. J. Hepatol. 2009; 51: 389-397.
62. van Werven JR. Hepatic unsaturated fatty acids in patients with non-alcoholic fatty liver disease assessed by 3.0T MR spectroscopy. Eur. J. Radiol. 2010; 75: e102-e107.
63. Fong Y, Bentrem D. CASH (Chemotherapy-Associated Steatohepatitis) costs. Ann. Surg. 2006; 243: 8-9.